Top Markets
Coin of the day
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.

2291
株式のランク #12476
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding... LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding entity, focuses globally on the research, development, production, and marketing of advanced interventional medical devices. The company provides an extensive range of solutions addressing various cardiovascular ailments. This includes specialized treatments for congenital heart defects, such as occluders for atrial septal, ventricular septal, and patent ductus arteriosus, along with necessary delivery systems and snare products. Additionally, it develops technologies for preventing cardioembolic stroke, offering occluders for the left atrial appendage and patent foramen ovale. Its portfolio also features a comprehensive selection of products for managing valvular diseases, including devices for aortic, mitral, tricuspid, and pulmonary valves, complemented by essential procedural accessories. Further offerings encompass vascular plugs and interatrial shunt devices. These medical technologies are primarily distributed to hospitals and through a network of distributors. Founded in 1994, the firm is headquartered in Shanghai, People's Republic of China, and operates as a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.
株価
$1.67
時価総額
$578.88M
変化(1日)
-2.39%
変化(1年)
-41.41%
CN
取引 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291)

カテゴリー

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.(2291)の収益
Aug 2026 時点の収益 TTM: 0
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
- -
DE